2014 Chabner Colloquium: Collaboration in Cancer Drug Trials

Date of Original Release:7/10/2014
Expiration Date:12/31/2014

Conference/Meeting Name

2014 Chabner Colloquium: Collaboration in Cancer Drug Trials



The Liberty Hotel

215 Charles Street

Boston, MA 02114 (map)




Monday - Tuesday, November 10 - 11, 2014



In the field of oncology, the rapid pace of discovery and a better understanding of prevention, detection, the microenvironment, and treatment of cancer will lead to improved patient outcomes. Accurately tailored cancer treatment and individualized therapy will focus on tumor biology and host factors. The healthcare provider will need to be well informed in order to provide the most effective therapy for a particular patient with the fewest associated risks and toxicities. In oncology, our understanding of the complexity of the disease is expanding at an exponential rate.


Learning Objectives

After successful completion of this educational activity, participants should be able to:

·        Explain the use of testing for EGFR mutations at diagnosis of NSCLC.

·        Explain the role of stress response pathways in the metabolic homeostasis of pancreatic cancer cells.

·        Discuss the molecular mechanisms regulating metabolism of cancer cells.

·        Describe the function of the mammalian sirtuin SIRT6, a histone deacetylase, in controlling expression of key metabolic and ribosomal genes during oncogenic transformation.

·        Discuss interpatient heterogeneity of advanced prostate cancer, clonal evolution with treatment, mechanisms of treatment resistance, and the use of novel therapeutic strategies.

·        Describe the role of immunotherapy in the treatment of cancer.

·        Explain the mechanisms of action for immune checkpoint antibodies.

·        Cite the side effects and management strategies for immune checkpoint antibodies.

·        Describe the landscape of recurrently mutated genes in AML.

·        Discuss the implications of intra-patient clonal heterogeneity in AML.

·        Review the somatic mutations that predict prognosis in MDS independent of existing clinical parameters.

·        Describe the key biological processes that are altered by genetic mutations in MDS, including RNA splicing, cohesin ring function, epigenetic regulation, kinase signaling, and transcription factors.

·        Discuss the molecular basis of lenalidomide activity in MDS.

·        Explain the biologic and prognostic role of TET2/IDH mutations in leukemia.

·        Explain the role of epigenetic therapies in TET2/IDH-mutant leukemias.

·        Describe the potential use of molecular analysis of circulating tumor cells for drug development in breast cancer.

·        Discuss the mechanisms of resistance to targeted therapies in lung cancer.

·        Explain the pathogenesis of IDH mutant cholangiocarcinoma.

·        Discuss EZH2 inhibition as a therapeutic target in SWI/SNF altered malignancies.

·        Discuss the translational implications of the finding that RNF43 is a frequently mutated gene in colorectal and endometrial cancers.Describe the role of serine metabolism in cancer.

·        Discuss the use of antifolates and related targets for cancer therapy.

·        Explain the prevalence of consequences of methylthioadenosine phosphorylase (MTAP) deficiency in cancer.

·        Describe the role of inhibitors of de novo purine synthesis (e.g., thioguanine) and their potential as effective treatment for patients with cancers lacking MTAP.

·        Explain the role of mitochondria in the proper functioning of cellular one-carbon metabolism.

·        Describe the relationship between one-carbon defects and mitochondrial disease manifestation.

·        Cite current genomic methods for profiling human tumors.

·        Describe the benefits and limitations of genomically focused clinical trial designs.


Target Audience

This activity is designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Society for Translational Oncology and The Massachusetts General Hospital. The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

The Society for Translational oncology designates this live activity for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


CME Credit

In order to receive CME credit, learners must sign-in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.) and attend the CME activity. Learners will be asked to complete an electronic activity evaluation following the meeting and indicate the number of credit hours claimed. Certificates will be provided upon completion of the evaluation.

To obtain CME credit, please visit: http://bit.ly/2014ChabnerCMECredit.


Financial Disclosures

In accordance with ACCME Standards for Commercial Support and the policies of the Society for Translational Oncology (STO), persons participating in this activity who are in a position to control the content have disclosed all relevant relationships with any commercial interest. On the basis of disclosed information, STO identifies and resolves all conflicts of interest before delivery of content.

STO staff involved in the development of this activity have nothing to disclose.

The following faculty have indicated that they have had relevant financial relationship(s) with a commercial interest within the past 12 months or that they have nothing to disclose.

Robert Bao, PhD; Nothing to disclose      

Aaron N. Hata, MD, PhD; Honoraria: Amgen, Inc

Nabeel Bardeesy, MD; Nothing to disclose            

F. Stephen Hodi, Jr, MD; Consultant/advisory role: (Uncompensated) Bristol-Myers Squibb, Merck, Genentech, Novartis. Research funding: (Funds to institution) Bristol-Myers Squibb, Merck, Genentech, Novartis

Aditya Bardia, MD, MPH; Nothing to disclose        

John Iafrate, MD; Intellectual property right/Inventor/patent: Bioreference Labs and Enzymatics INC. Consultant/advisory role: Enzymatics, Constellation, Chugai and DebioParm. Ownership interest: Enzymatics

Joseph R. Bertino, MD; Nothing to disclose           

Ross L. Levine, MD; Consultant/advisory role: Agios Pharmaceuticals

Bruce A. Chabner, MD; Consultant/advisory role: Merrimack Pharmaceuticals, Sanofi, Epizyme. Employment: PharmaMar (Board of Directors). Expert testimony: Eli Lilly. Ownership interests: PharmaMar (Zeltia), Pharmacyclics, Gilead, Exelixis, Celgene, Seattle Genetics        

Raul Mostoslavsky, MD, PhD; Nothing to disclose

Gregory M. Cote, MD, PhD; Consultant/advisory role: Advance Medical. Research funding: Chordoma Foundation        

Steven A. Rosenberg, MD, PhD; Nothing to disclose

Johann S. de Bono, MB ChB, FRCP, MSc, PhD ; Consultant/advisory role: Johnson & Johnson, Astellas, Medivation, AstraZeneca, Sanofi. Research funding: AstraZeneca, Sanofi, Genentech           

David Ryan, MD; Consultant/advisory role: MedImmune, LLC

Benjamin L. Ebert, MD; Consultant/advisory role: Genoptix, Inc, Celgene. Research funding: Celgene

Supriya Saha, MD, PhD; Nothing to disclose

Soldano Ferrone, MD, PhD; Nothing to disclose

David Solit, MD; Consultant/advisory role: Pfizer, Inc

Keith Flaherty, MD; Employment: Clovis Oncology (Board of Directors), Loxo Oncology (Board of Directors). Consultant/advisory role: Glaxo SmithKline, Roche, Sanofi, Momenta, Astex, Ziophram and Viralytics

Matthew Vander Heiden, MD, PhD; Consultant/advisory role: Agios Pharmaceuticals. Ownership interest: Agios Pharmaceuticals

Marios Giannakis, MD, PhD; Nothing to disclose  

Timothy A. Graubert, MD; Consultant/advisory role: Genoptix, Inc



Monday, November 10, 2014

8:00 a.m.         Welcome and Introductions: Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology 

Session 1: New Insights into Metabolic Regulation of Cancer Growth – Bruce A. Chabner, MGH, Moderator

  8:15 a.m.

  Nabeel Bardeesy (MGH)

 Insights into Pancreatic Cancer Metabolism

  9:00 a.m.

  Raul Mostoslavsky (MGH)

 The Histone Deacetylase SIRT6: Linking Epigenetics to Cancer Metabolism 

  9:45 a.m.

  Johann de Bono (ICR, Royal Marsden, Surrey, UK)

 Improving the Treatment of Prostate Cancer

10:30a.m. – 10:45 a.m.  Beverage Break

Session 2: Immunotherapy – Soldano Ferrone, MGH, Moderator

 10:45 a.m. 

  Steven A. Rosenberg (NCI)

 Curative Potential of Cell Transfer Immunotherapy for Cancer

 11:45 a.m.

  F. Stephen Hodi, Jr (DFCI)

  Immune Checkpoint Therapy

12:30p.m. – 1:30 p.m.   Lunch Buffet (provided by STO)

Session 3: Hematological Malignancies - Timothy A. Graubert, MGH, Moderator

  1:30 p.m.

  Timothy A. Graubert (MGH) 

  Molecular Profile of Acute Myeloid Leukemia (AML)

  2:15 p.m.

  Benjamin L. Ebert (BWH)

  Understanding Myelodysplastic Syndromes (MDS)

  3:00 p.m.

  Ross L. Levine (MSKCC)

 Pathogenesis and Therapy of         IDH/TET- mutant Myeloid Malignancies

3:45 p.m. – 4:00 p.m.    Beverage Break

Session 4: Junior Faculty Forum - Joseph R. Bertino, RCI, Moderator

  4:00 p.m.

  Aditya Bardia (MGH)

  Molecular Interrogation of Circulating  Tumor Cells for Drug Development in Breast Cancer

  4:15 p.m.

  Aaron N. Hata (MGH)

 Evolution of Acquired Resistance to    Targeted Therapies in Lung Cancer

  4:30 p.m.

  Supriya Saha (MGH)

 From Model Systems to Novel Therapeutics: Understanding IDH Mutant Cholangiocarcinoma

  4:45 p.m.

  Gregory M. Cote (MGH)

 Targeting EZH2 in SWI/SNF Altered Sarcomas

  5:00 p.m.

  Marios Giannakis (DFCI)

 Late Breaking Advances: RNF43 Mutations in Colorectal and Endometrial Cancers

5:20 p.m.         Adjourn Day 1



Tuesday, November 11, 2014

7:50 a.m.         Welcome and Introductions, Day 2: Martin J. Murphy, DMedSc, PhD, Convener, Society for Translational Oncology 

Session 5: Metabolic Lesions in Cancer - David Ryan, MGH, Moderator

 8:00 a.m.

  Matthew Vander Heiden (MIT) 

  Serine Metabolism and Cancer

  8:45 a.m.

  Joseph R. Bertino (RCI)

Exploiting Methylthioadenosine Phosphorylase Deletion in Cancer


  Robert Bao (MGH)

Systematic Analysis of the Cellular Response to Mitochondrial Dysfunction

10:15 a.m. -10:30 a.m.         Beverage Break

Session 6: Genetic Profiling for Treatable Mutations - Keith Flaherty, MGH, Moderator

  10:30 a.m.

  A. John Iafrate (MGH)  

  Advances in Molecular Screening:  NGS

  11:15 a.m.

  David Solit (MSKCC)

 Lessons From the Study of  Extraordinary Responders

  12:00 p.m.

  Bruce A. Chabner (MGH)

  Closing Remarks

12:15 p.m. – Adjourn Day 2,   Lunch Buffet



STO gratefully acknowledges educational grants in partial support of this activity from:

Chugai Academy for Advanced Oncology (CHAAO)          


Incyte Corporation

Lilly USA, LLC

Merrimack Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Prometheus Laboratories, Inc

sanofi-aventis US

Sigma-Tau Pharmaceuticals, Inc


Americans With Disabilities (ADA)

If disability accommodations (e.g., communication access, alternate formats) are needed to participate fully in this event, please contact [name] at [phone number and email address].



Effective August 1, 2013, The Centers for Medicare & Medicaid Services (CMS) required reporting of any direct or indirect payments made to any US Healthcare Professional by pharmaceutical and device manufacturers and applicable group purchasing organizations (GPOs) under its Open Payments program.

In order to comply with the requirements of the pharmaceutical and device manufacturers who have provided support for this CME activity, no food and beverage costs associated with this activity have been covered by their funding. Therefore, there has been no indirect payment or transfer of value for your attendance at this meeting. NO data regarding your participation at this meeting will be reported to CMS.